wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37024369-051D02C7-6E35-4360-82C9-80A943E594A8
Q37024369-051D02C7-6E35-4360-82C9-80A943E594A8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37024369-051D02C7-6E35-4360-82C9-80A943E594A8
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protoc
P2860
Q37024369-051D02C7-6E35-4360-82C9-80A943E594A8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37024369-051D02C7-6E35-4360-82C9-80A943E594A8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c1d88acf28e6fe60aa437774bed7b562293c0e11
P2860
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.